Literature DB >> 24371562

IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.

Roland Fiskesund1, Jun Su1, Ivana Bulatovic2, Max Vikström3, Ulf de Faire4, Johan Frostegård1.   

Abstract

BACKGROUND: We have reported that anti-phosphorylcholine (anti-PC) IgM is a protection marker for human cardiovascular disease (CVD) and atherosclerosis. We here investigate the anti-PC autoantibodies in a well-defined cohort with regard to idiotype, atherosclerosis progression and mechanisms for its protective action.
METHODS: Serum levels and binding specificities of different anti-PC isotypes were determined in 226 hypertensive individuals enrolled in European Lacidipine Study on Atherosclerosis using ELISA. The mean of the maximum Intima-Media Thicknesses (IMT) in the far walls of common carotids and bifurcations was assessed at the time of inclusion, and four years afterwards. Apoptosis in immune cells was induced with lysophosphatidylcholine (LPC) and quantified using the MTT-assay.
RESULTS: Anti-PC IgM, IgA and IgG1 (but not IgG2) was negatively associated with IMT-progression. Combining anti-PC IgM with data on antibodies against oxidized- and malondialdehyde-modified LDL further strengthened this association. At very high levels, anti-PC IgM exhibited a striking negative association with atherosclerosis progression (OR 0.05; CI 0.006-0.40). Analysis of serum samples taken four years apart in study participants affirmed the stability of anti-PC IgM titers over time. Examination of fine specificities revealed that the protective isotypes (IgM, IgA and IgG1) are of the Group I idiotype whereas the non-protective IgG2 subclass was Group II. Anti-PC IgM inhibited LPC-induced cell death of immune cells.
CONCLUSION: Group I anti-PC antibodies, particularly of the IgM class, are independent protection markers for atherosclerosis progression. One potential mechanism of action is inhibition of LPC-induced cell cytotoxicity.

Entities:  

Keywords:  Antibodies; Apoptosis; Biomarkers; Carotid intima media thickness; Phosphorylcholine

Year:  2012        PMID: 24371562      PMCID: PMC3862347          DOI: 10.1016/j.rinim.2012.01.001

Source DB:  PubMed          Journal:  Results Immunol        ISSN: 2211-2839


  37 in total

1.  Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids.

Authors:  Jaewoo Choi; Wujuan Zhang; Xiaodong Gu; Xi Chen; Li Hong; James M Laird; Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2010-10-25       Impact factor: 3.739

2.  Phosphorylcholine-targeting immunization reduces atherosclerosis.

Authors:  Giuseppina Caligiuri; Jamila Khallou-Laschet; Marta Vandaele; Anh-Thu Gaston; Sandrine Delignat; Chantal Mandet; Heinz V Kohler; Srini V Kaveri; Antonino Nicoletti
Journal:  J Am Coll Cardiol       Date:  2007-07-23       Impact factor: 24.094

3.  Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.

Authors:  Jun Su; Anastasia Georgiades; Ruihua Wu; Thomas Thulin; Ulf de Faire; Johan Frostegård
Journal:  Atherosclerosis       Date:  2005-11-22       Impact factor: 5.162

4.  Autoantibodies to OxLDL are decreased in individuals with borderline hypertension.

Authors:  R Wu; U de Faire; C Lemne; J L Witztum; J Frostegård
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

5.  Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse.

Authors:  Q S Mi; L Zhou; D H Schulze; R T Fischer; A Lustig; L J Rezanka; D M Donovan; D L Longo; J J Kenny
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 6.  Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis.

Authors:  P Holvoet; D Collen
Journal:  Atherosclerosis       Date:  1998-04       Impact factor: 5.162

7.  Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden.

Authors:  Hans Grönlund; Göran Hallmans; Jan Håkan Jansson; Kurt Boman; Max Wikström; Ulf de Faire; Johan Frostegård
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-06

8.  Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis.

Authors:  O W Portman; M Alexander
Journal:  J Lipid Res       Date:  1969-03       Impact factor: 5.922

9.  IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells.

Authors:  Yifang Chen; Yong-Beom Park; Ekta Patel; Gregg J Silverman
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

10.  Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism.

Authors:  Ulf de Faire; Jun Su; Xiang Hua; Anna Frostegård; Mats Halldin; Mai-Lis Hellenius; Max Wikström; Ingrid Dahlbom; Hans Grönlund; Johan Frostegård
Journal:  J Autoimmun       Date:  2009-09-02       Impact factor: 7.094

View more
  12 in total

1.  Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE?

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Nat Rev Rheumatol       Date:  2016-06-30       Impact factor: 20.543

Review 2.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

3.  Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.

Authors:  Anna G Frostegård; Jun Su; Xiang Hua; Max Vikström; Ulf de Faire; Johan Frostegård
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

4.  IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome.

Authors:  Eva Cecilie Knudsen; Ingebjørg Seljeflot; Tonje Amb Aksnes; Jan Eritsland; Harald Arnesen; Geir Øystein Andersen
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

5.  Potential natural immunization against atherosclerosis in hibernating bears.

Authors:  Shailesh Kumar Samal; Ole Fröbert; Jonas Kindberg; Peter Stenvinkel; Johan Frostegård
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 6.  Immunity, atherosclerosis and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  BMC Med       Date:  2013-05-01       Impact factor: 8.775

Review 7.  Immune mechanisms in atherosclerosis, especially in diabetes type 2.

Authors:  Johan Frostegård
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-29       Impact factor: 5.555

8.  CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Juying Han; Gospel Enyindah-Asonye; Feng Lin; Jonathan D Smith
Journal:  BMC Res Notes       Date:  2018-04-03

9.  Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.

Authors:  S K Samal; A R Qureshi; M Rahman; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

10.  Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.

Authors:  Sofia Ajeganova; Maria L E Andersson; Johan Frostegård; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2021-07-27       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.